Revance News and Activities

Revance is a company listed under the stock ticker RVNC (US).

They are in:

• Biotechnology33%
• Pharmaceuticals33%
• Other33%

Acquisition, funding and merger involving Revance.

• Crown Laboratories has acquired Revance (posted on February 9 2025).
• Revance has announced the acquisition of Revance  (posted on January 14 2025).
• Crown Laboratories and Revance have announced they will merge  (posted on August 14 2024)..

View the org chart displaying its 46 main executives

Most searched biographies at Revance

• Nadeem Moiz, Chief Executive Officer
• William Meury, Director
• Jeff Bedard, Executive Chairman of the Board

Popular executive movements at Revance

• Michael Mckenna, Executive Vice President and Chief Sales Officer, Aesthetics, has left the company  (posted on April 3 2026).
• Steve Kreider has joined the company as Executive Vice President, Chief Revenue Officer  (posted on January 12 2026).
• Kira Schwartz has joined the company as Chief Legal Officer  (posted on October 2 2025).

Click here to view some more movements at Revance

Create your alert
to follow the executive moves at Revance.

Revance has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Revance

• Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Revance Therapeutics, Inc.
• Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference - Revance Therapeutics, Inc.
• Revance to Participate in the William Blair 42nd Annual Growth Stock Conference - Revance Therapeutics, Inc.
• Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update - Revance Therapeutics, Inc.
• Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022 - Revance Therapeutics, Inc.
• Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting - Revance Therapeutics, Inc.
• Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Revance Therapeutics, Inc.
• Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference - Revance Therapeutics, Inc.
• Revance to Participate in the Wells Fargo Securities Healthcare Conference - Revance Therapeutics, Inc.
• Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers - Revance Therapeutics, Inc.
• View more press releases Close

Social media about Revance

• Revance on Wikipedia, Google News & Yahoo Finance
• Revance on LinkedIn, X (Twitter) & YouTube